AERIE PHARMACEUTICALS INC (AERI) Stock Price, Quote, News and Overview
NASDAQ:AERI - Nasdaq - US00771V1089 - Common Stock - Currency: USD
AERI Quote, Performance and Key Statistics
15.25
+0.01 (+0.07%)
The current stock price of AERI is 15.25 USD. In the past month the price increased by 0.26%. In the past year, price increased by 51.89%.
AERI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About AERI
Company Profile
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. The company is headquartered in Durham, North Carolina and currently employs 376 full-time employees. The company went IPO on 2013-10-25. The firm is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The firm's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.
Company Info
AERIE PHARMACEUTICALS INC
4301 Emperor Boulevard, Suite 400
Durham NORTH CAROLINA 27703 US
CEO: Vicente Anido Jr
Employees: 376
Company Website: https://aeriepharma.com/
Phone: 19192375300.0
AERIE PHARMACEUTICALS INC / AERI FAQ
What is the stock price of AERIE PHARMACEUTICALS INC today?
The current stock price of AERI is 15.25 USD. The price increased by 0.07% in the last trading session.
What is the ticker symbol for AERIE PHARMACEUTICALS INC stock?
The exchange symbol of AERIE PHARMACEUTICALS INC is AERI and it is listed on the Nasdaq exchange.
On which exchange is AERI stock listed?
AERI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AERIE PHARMACEUTICALS INC stock?
14 analysts have analysed AERI and the average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25. Check the AERIE PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AERIE PHARMACEUTICALS INC worth?
AERIE PHARMACEUTICALS INC (AERI) has a market capitalization of 753.62M USD. This makes AERI a Small Cap stock.
How many employees does AERIE PHARMACEUTICALS INC have?
AERIE PHARMACEUTICALS INC (AERI) currently has 376 employees.
What are the support and resistance levels for AERIE PHARMACEUTICALS INC (AERI) stock?
AERIE PHARMACEUTICALS INC (AERI) has a support level at 15.23 and a resistance level at 15.26. Check the full technical report for a detailed analysis of AERI support and resistance levels.
Is AERIE PHARMACEUTICALS INC (AERI) expected to grow?
The Revenue of AERIE PHARMACEUTICALS INC (AERI) is expected to grow by 23.8% in the next year. Check the estimates tab for more information on the AERI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AERIE PHARMACEUTICALS INC (AERI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AERI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AERI, evaluating the profitability, health, valuation and growth aspects
- AERIE PHARMACEUTICALS INC (AERI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AERIE PHARMACEUTICALS INC (AERI) Sales and EPS estimates to see what analysts future expectations are.
- AERIE PHARMACEUTICALS INC (AERI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AERIE PHARMACEUTICALS INC (AERI) Insider and Institutional Ownership to learn about the owners and their transactions.
- AERIE PHARMACEUTICALS INC (AERI) Stock Chart to make your own analysis
- AERIE PHARMACEUTICALS INC (AERI) Latest news and press-releases to stay up to date.
Does AERIE PHARMACEUTICALS INC (AERI) stock pay dividends?
AERI does not pay a dividend.
When does AERIE PHARMACEUTICALS INC (AERI) report earnings?
AERIE PHARMACEUTICALS INC (AERI) will report earnings on 2023-02-22.
What is the Price/Earnings (PE) ratio of AERIE PHARMACEUTICALS INC (AERI)?
AERIE PHARMACEUTICALS INC (AERI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
AERI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AERI. When comparing the yearly performance of all stocks, AERI is one of the better performing stocks in the market, outperforming 98.08% of all stocks.
AERI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AERI. There are concerns on the financial health of AERI while its profitability can be described as average.
AERI Financial Highlights
Over the last trailing twelve months AERI reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 94.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -17.09% | ||
| ROA | -9.73% | ||
| ROE | N/A | ||
| Debt/Equity | -1.91 |
AERI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to AERI. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -85.62% and a revenue growth 23.8% for AERI